Tag Archives: Teva

Product-by-process claims are product claims

This is being published with the permission of Kawaguti & Partners.    K&P’s Court Decision Report in 2015 <<<Special News Flash>>>   Supreme Court Overturns Grand Panel’s Decision of IPHC and Admits that “Product-by Process” Claim should Cover Same Products … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , | Leave a comment

Teva v. Sandoz: “Just the facts, Ma’am”

Effectively reversing Cybor Corp., which flatly stated that a lower court’s claim construction is a question of law which is to be reviewed de novo by the Fed. Cir., yesterday the Supreme Court held 7-2 that questions of fact resolved … Continue reading

Posted in Claim Interpretation | Tagged , , , , , , , , | Leave a comment

The “Top Ten” IP Stories of 2014 (Most “Definitely”)

I don’t think I can recall a more action-packed year for intellectual property law in my career, much less during the almost six years that I have been writing this blog. I am trying to write this while in transit, … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Cert. Granted In Teva V. Sandoz (“April Fool” Lightning Ballast!)

On Monday, the Supreme Court granted cert. in the somewhat overlooked panel decision, Teva Pharm., Inc. v. Sandoz, Inc., 727 F.3d 1363 (Fed. Cir. 2013)(Sup. Ct. 13-854) (a copy can be found at the end of this post). Most commentators … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , | 1 Comment